lscfa wrote: First I hear of this....
The Corporation is developing 12 barium contrast products (HDXba, MultiXba, MultiXthin, MutiXS, SmoothX, BarXnectar, BarXthin, BarXhoney, Barpudding, LumenX, VisionX and TagX) for sale into the radiology pharmaceutical market. The Corporation submitted five of the products for registration to Health Canada and received approvals and issuance of licenses as follows:
SmoothX – February 10, 2021 (1 micron liquid)
HDXba – February 10, 2021 (10 micron powder)
MultiXba – March 31, 2021 (1micron powder)
MultiXthin – April 26, 2021 (1 micron liquid)
MultiXS – May 11, 2021 (10 micron liquid)
Product names are subject to change due to regulatory approval processes.
Voyageur plans to expand its barium contrast range by advancing the development of additional barium contrast products, including multiple barium swallow products for the diagnosis of dysphagia. This market has been identified as a potential high growth area, with a range estimated as being as high as 22% of the population over 50 years of age affected by dysphagia.